Nifty 17359.55 (-0.24%)
Sensex 58433.35 (-0.05%)
Nifty Bank 36527.85 (0.05%)
Nifty IT 36094.65 (-0.17%)
Nifty Financial Services 17970.95 (-0.07%)
Adani Ports 743.10 (0.54%)
Asian Paints 3152.05 (-0.90%)
Axis Bank 677.85 (0.26%)
B P C L 384.50 (1.49%)
Bajaj Auto 3322.00 (-0.19%)
Bajaj Finance 7128.00 (-0.73%)
Bajaj Finserv 17689.80 (-0.38%)
Bharti Airtel 721.30 (-1.54%)
Britannia Inds. 3570.15 (-0.23%)
Cipla 910.20 (-1.20%)
Coal India 159.05 (-0.16%)
Divis Lab. 4738.70 (-0.81%)
Dr Reddys Labs 4610.00 (-1.13%)
Eicher Motors 2477.00 (1.04%)
Grasim Inds 1733.85 (0.58%)
H D F C 2784.85 (-0.82%)
HCL Technologies 1173.00 (-0.99%)
HDFC Bank 1521.05 (-0.31%)
HDFC Life Insur. 702.10 (-0.45%)
Hero Motocorp 2483.50 (0.44%)
Hind. Unilever 2364.25 (-0.80%)
Hindalco Inds. 427.50 (-1.06%)
I O C L 122.00 (1.12%)
ICICI Bank 722.20 (-0.03%)
IndusInd Bank 946.45 (0.10%)
Infosys 1761.55 (0.76%)
ITC 223.50 (-0.86%)
JSW Steel 648.10 (0.21%)
Kotak Mah. Bank 1970.10 (0.30%)
Larsen & Toubro 1815.15 (1.45%)
M & M 847.95 (-0.19%)
Maruti Suzuki 7270.00 (-0.75%)
Nestle India 19145.60 (-1.83%)
NTPC 127.50 (-0.93%)
O N G C 145.35 (0.94%)
Power Grid Corpn 214.95 (0.21%)
Reliance Industr 2463.55 (-0.78%)
SBI Life Insuran 1169.10 (-1.60%)
Shree Cement 26269.05 (-0.08%)
St Bk of India 476.15 (-0.18%)
Sun Pharma.Inds. 757.50 (-1.14%)
Tata Consumer 771.10 (-0.28%)
Tata Motors 478.25 (-0.18%)
Tata Steel 1105.40 (-0.63%)
TCS 3635.45 (-0.20%)
Tech Mahindra 1616.05 (-0.83%)
Titan Company 2379.65 (-0.29%)
UltraTech Cem. 7393.50 (0.96%)
UPL 703.50 (0.76%)
Wipro 642.80 (-0.62%)

Aurobindo pharma Q2 profits were gravely hit by decline in generic prices in the US, net profit declined by 13.5% YoY and 9.5% QoQ

by 5paisa Research Team 11/11/2021

In Q2FY22, the company generated net profit of Rs. 6,970mn, down by 13.5% YoY and down by 9.5% QoQ. This effect mainly came from the elevated generic price erosion in the US as channels try to liquidate excess stocks, putting pressure on prices. 


However, US sales grew 7.2% YoY and 10.2% QoQ at US $401m on volume gain in existing products and new launches from the acquired portfolio stood at US $9m sales and Base generic sales (excluding injectables and Natrol) at US $310m grew 8.9% YoY and 13.1% QoQ while generic injectable sales at US $68m grew 5.9% YoY and 9.5% QoQ. Global generic injectables sales were at USD105m (USD68m from the US) in 2Q.

The company has filed for 27 ANDAs including 5 injectables during 2Q (35 filings in 1HFY22 including 7 injectables) and plans to file another 50-55 filings each year for next two years. The company received final FDA approvals for 7 ANDAs including 2 injectables in 2Q which makes a total of 11 approvals in 1H including 5 injectables). It launched 6 products including 3 injectables in 2Q which totals to 11 launches, including 3 injectables during 1HFY22.

The revenues from European markets stood at Rs. 16.6bn and grew 9.7% YoY and 5% QoQ. According to ARBP, there’s still a lot of potential for sales growth in Europe mainly on account of improving capacity utilization (including the penem block), increasing supplies from India (including generic injectables from Unit 4) and rising filings for oncology products (55 dossiers filed of which 12 are approved. There’s also been improvement in profitability for Europe sales with current operating margins in mid-teens which were only in single-digit margins in previous year. 

For Q2 segment wise, RoW revenues stood at Rs. 3.9bn which declined 13.5% YoY on a high base while the sales grew at 17.3% QoQ on patient volume recovery, ARV revenues stood at Rs. 1.5bn which declined at 71.2% YoY and 51.1% QoQ due to lower demand on higher procurement by channels in previous year amid COVID-19 uncertainties and API revenues stood at Rs. 7.8bn which declined 5.8% YoY and 3.9% QoQ on lower demand.

Moving forward, it is estimated that the US segment (~50% of revenues) would remain steady despite visible challenges, the generic sales (excluding injectables) would grow at single-digit sales on account of consistent new launches and volume gains in launched products, and injectables portfolio could also hold strong growth on new launches and patient footfalls recovery in key markets. The company reaffirmed its goal of achieving global sales of US $650-700m from generic injectables by FY24 through portfolio and capacity expansion. Capacity utilization improvement (e.g. for penem block) and completion of Vizag plant should help injectables sales.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

These Penny stocks are locked in the upper circuit on Thursday, November 11!

These Penny stocks are locked in the upper circuit on Thursday, November 11!
by 5paisa Research Team 11/11/2021

The BSE Sensex is trading weak, down by 550 points on Thursday. The shares of Titan, Tata Steel and RIL are seen trading in green, while all the other BSE Sensex constituents are seen trading in red on Thursday.

BSE Smallcap index is down by 0.40% and is seen outperforming BSE Sensex. BSE Midcap index has slipped by 0.80% and is performing in line with the BSE Sensex.

Top BSE Midcap index gainers are CRISIL, up by more than 9%, GICRE – up by more than 4%, Sona BLW Precisions up - 3% and Trent which is up by more than 2%. Bharat Forge is the top BSE Midcap loser in the Thursday trading session.

The shares of Yes bank are trading with more than 2% gains on an intraday basis.

The shares of Inflame Appliances, Brightcom Group and Kotyark Industries are seen locked in the upper circuit on an intraday basis in the Thursday trading session. Goldstone Technologies shares are also seen outperforming and are locked in the upper circuit on an intraday basis.

The shares of Salzer Electronics made a fresh 52-week high while Jain Irrigation shares are seen trending ahead of its results on November 13.

Following is the list of Penny Stocks that are locked in the upper circuit on Thursday:

Sr No   

Stock   

LTP   

Price Gain (%)   

1  

Sintex Industries   

8.05  

4.55  

2  

Unitech   

2.2  

4.76  

3  

FCS Software   

1.6  

3.23  

4  

Orient Green Power   

5.6  

4.67  

5  

Sintex Plastics Technology   

9.1  

4.6  

6  

Llyods Steels   

7.6  

4.83  

7  

Gammon Infra   

1.5  

3.45  

8  

Prakash Steel   

3.2  

4.92  

9  

SITI Networks   

1.95  

2.63  

10  

SREI Infra Finance  

5.75  

4.55  

11  

SEL Manufacturing   

7.4  

4.96  

12  

Ankit Metal and Power   

6.35  

4.96  

13  

Sundaram Multi Pap   

2.2  

4.76  

14  

JIK Industries   

0.65  

8.33  

15  

LCC Infotech   

2.1  

5  

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

These Low-Priced stocks are locked in the upper circuit on Thursday, November 11

These Low-Priced stocks are locked in the upper circuit on Thursday, November 11
by 5paisa Research Team 11/11/2021

Amid the selling pressure witnessed in equity markets, a couple of low-price shares were seen shining in Thursday’s trading session.

On Thursday, the benchmark indices are seen trading in red. BSE Sensex has rattled more than 500 points and is trading 0.87% lower at the 60,352.82 level.

Within the stocks in Sensex, Titan is the top BSE Sensex gainer up by more than 1% shining in the bearish trend shown by the market, while Tech Mahindra is the top BSE Sensex loser on Thursday, plunging beyond 2%.

Along with Titan, Tata Steel and Reliance Industries are seen to be the only BSE Sensex gainers. The broader market is seen trading under pressure in Thursday’s trading session with BSE Midcap trading 0.74% lower and BSE Smallcap trading 0.42% down.

Monte Carlo Fashions, Thermax, Aurum Proptech, Narayana Hrudayalaya and Timken India are among the top BSE smallcap index gainers on Thursday.

Crisil, General Insurance Corporation of India, Sona BLW Precision Forgings, Trent and Endurance Technologies are the top-performing BSE Midcap index constituents. Bharat Forge is experiencing the highest drag in the BSE Midcap stocks pack on Thursday.

The sectoral indices are also depicting a bearish trend in Thursday’s trading session. BSE Realty is down by more than 2% and BSE Bankex is down more than 1%.

The price-volume breakout is seen in some of the low-priced stocks on Thursday with several stocks being locked in the upper circuit.

Following is the list of low-priced stocks that are locked in the upper circuit in Thursday’s trading session:

Sr No   

Stock   

LTP   

Price Gain (%)   

1  

3i Infotech   

66.75  

4.95  

2  

Brightcom Group   

91.5  

4.99  

3  

Energy Development Company   

12.35  

4.66  

4  

Parsvanath Development   

19.55  

9.83  

5  

RattanIndia Enterprises   

51.35  

4.9  

6  

Hilton Metal   

16.25  

4.84  

7  

Indowind Energy   

12.4  

4.64  

8  

Globe Textile   

14.8  

4.96  

9  

Digjam   

44.85  

4.91  

10  

Kotyark Industries   

53.05  

4.95  

11  

Oswal Agro Mill   

20.3  

4.91  

12  

Atlanta   

21.65  

4.84  

13  

Williamson Magor   

37  

9.96  

14  

Soma Textiles   

11.4  

4.59  

15  

Laxmi Cotspin   

26  

4.84  

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Zomato’s net loss for the quarter widens to Rs 430 crore

Zomato’s net loss for the quarter widens to Rs 430 crore
by 5paisa Research Team 11/11/2021

The stock is trending for its acquisitions and is up by 3% today.

Zomato is hitting the headlines again for two reasons: one for the quarterly results it has announced for the quarter ended September, and secondly for making significant investments in three companies. It posted both the announcements after market hours on 10 November 2021.

Talking about the financials, the company was able to achieve strong sales growth in Q2FY22. The sales increased to Rs 1,024 crore, up by about 21% when compared to the previous quarter. Even though there has been a great development in the top-line, the bottom has suffered a heavy blow. The net loss widened to Rs 430 crore as it stood at Rs 356 crore in the previous quarter. The company has been aggressively spending on branding and marketing for customer acquisition, and the contribution from smaller geographies (which are currently less profitable) is increasing, resulting in increasing net losses.

The company also announced the acquisition of a 16.1% stake in Samast Technologies Pvt Ltd (magicpin) through a cash consideration of Rs 371 crore against convertible preference shares. In the same fashion, it acquired a 7.89% stake in Bigfoot Retail Solutions Pvt Ltd (Shiprocket) for a cash consideration of Rs 57 crore. The board also has approved the acquisition of 6.4% of Curefit Healthcare Pvt Ltd (Curefit).

Zomato has been one of the buzzing stocks on Dalal Street ever since the filing of IPO news came out in the market. Zomato was already a popular online food delivery company before it became public. The recent trend of loss-making firms filing for IPO and getting higher valuations was initially set by Zomato. The company opened with a price of Rs 125.85 on the BSE on July 23, 2021. The stock created its all-time high of Rs 152.75 at the beginning of September and has displayed high volatility behaviour throughout. It is currently trading near the level of Rs 138.8. The stock has a 52-week low of Rs 114.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Navin Fluorine bags a multi-year contract worth Rs 800 crore

Navin Fluorine bags a multi-year contract worth Rs 800 crore
by 5paisa Research Team 11/11/2021

Navin Fluorine International Limited manufactures and sells speciality fluorochemicals in India and internationally. The speciality chemical has rallied 41% in last one year but was out of favour recently on account of quarterly results which failed to impress the market participants.

An Arvind Mafatlal Group company, it primarily focuses on fluorine chemistry - producing refrigeration gases, inorganic fluorides, speciality organofluorines and offers Contract Research and Manufacturing Services. Its manufacturing facilities are located at Surat in Gujarat and Dewas in Madhya Pradesh.

Navin Fluorine Advanced Sciences Limited (‘NFASL’), a wholly-owned subsidiary of the company, has entered into a multi-year contract with a large multinational company for the manufacture and supply of a key agrochemical fluoro intermediate, the company informed in its exchange filing on November 10.

The project is expected to strengthen the product offerings as well as customer relationships along with providing building blocks for future growth with a peak revenue potential of Rs 150 to 170 crore per annum. The project will entail an investment of Rs 125 crore, which includes an approximate investment of Rs 14 crore for the expansion of the effluent treatment plant. The facility will be located at Dahej, in the state of Gujarat and will be funded through a mix of internal accruals and debt. The supplies are expected to commence by end of FY23.

“We continue to strengthen our leadership position in fluorine chemistry and look forward to further growing our key partnerships,“ stated Radhesh Welling, Managing Director of Navin Fluorine.

The Rs 800 crore multi-year deal is touted as a tailwind for the speciality chemical manufacturer and such the stock has shown some strength amid the positive sentiment for the bagged deal.

The stock is currently trading at Rs 3600.85 with a gain of 3.01% at 12.41 pm.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Affle (India) is gaining momentum with stellar Q2 numbers

Affle (India) is gaining momentum with stellar Q2 numbers
by 5paisa Research Team 11/11/2021

The stock zoomed 6% after an excellent Q2-FY22 result.

This stock was listed on NSE two years back, and from the listing date, it has registered 580% returns in a short period of 25 months.

Unbelievable returns, right. The company is able to generate this huge return with its unique business model, robust financial performance, and efficient management.

Business model

Affle India is a technology company with a proprietary consumer intelligence platform that delivers consumer acquisitions, engagements, and transactions through relevant mobile advertising.

In simple terms, when you browse in any e-commerce website, you look for some products, those data points will be collected by Affle and it will be retargeted to existing consumers to complete transactions. This is their major revenue driver.

Around 97% of revenue is made from new consumer conversions (acquisitions, engagements, and transactions) through relevant mobile advertising, retargeting existing consumers to complete transactions for e-commerce companies, An online to offline (“O2O”) platform that converts online consumer engagement into in-store walk-ins.

Unbelievable growth in numbers

In the last three years from FY18 to FY21, revenue has grown at a CAGR of 46% and profit has grown at a CAGR of 69% which shows the steep growth of the company. The operating margin is stable in the range of 25% to 28% for the last three years.

Yesterday Q2 numbers were out and the stock zoomed 6% after the Q2-FY22 report. Net sales grew 103% on a YoY basis stood at Rs 274 crore, EBITDA grew by 51.1% on a YoY basis to Rs 52.1 crore, Net profit jumped 77.2% on a YoY basis to Rs 47.82 crore.

Future growth prospects

The company continues to witness a strong market opportunity with advertisers consistently accelerating their digital spending, resulting in persistent, broad-based growth across their top industry verticals coming from both Indian and International markets.

Mobile advertising has huge potential due to rapid growth in Smartphone penetration, cost-effective packages, majority population in India is between 18-30, their usage of smartphones is relatively more and targeting them would be much easy.

Valuation

Companies like these will definitely trade in premium. It is trading at a TTM P/E of 300x against industry P/E of 88.17x. It is clearly higher in valuation.

Do you feel fundamentals and company performance would justify it?

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order